This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
3/6/15 5:30AM
AbbVie announced it is buying cancer drug-maker Pharmacyclics for $21 billion.
3/5/15 10:05AM
The $21 billion price tag for Pharmacylics only earns AbbVie rights to 50% of the blood cancer drug Imbruvica.
3/5/15 6:38AM
The new Opdivo approval covers patients with squamous non-small cell lung cancer no longer responsive to chemotherapy, according to an announcement made the FDA.
3/4/15 1:47PM
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
3/4/15 1:08PM
Obese Americans taking Contrave to lose weight cut their risk of having a heart attack, stroke or dying from heart disease by almost half compared to people taking a placebo.
3/3/15 11:51AM
The slow commercial launch of the inhaled insulin Afrezza coupled with growing downward pricing pressure for all diabetes products compels Goldman Sachs to slap a 'sell' rating on MannKind.
3/3/15 8:16AM
Chugai decision to license MultiStem for Japan will look prescient or foolish depending on the stem cell therapy's performance in an ongoing phase II study of stroke patients.
3/2/15 9:38AM
Afrezza is "modestly effective" at reducing blood glucose and its long-term safety is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.
3/2/15 8:15AM
Amgen believes proving Kyprolis' superiority over Velcade in the second-line multiple myeloma treatment setting further justifies the $10.4 billion paid to Onyx Pharmaceuticals.
3/1/15 10:25PM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
2/27/15 6:00AM
To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.
2/25/15 11:47AM
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.
2/25/15 7:55AM
Later this quarter, Vertex Pharmaceuticals will be disclosing new clinical data on its next cystic fibrosis drug, VX-661. Here's a preview.
2/23/15 11:06AM
The U.S. launch of Orexigen's obesity pill Contrave is outpacing the competition.
2/20/15 3:47PM
Activist hedge fund Sarissa Capital is starting a proxy fight to force the ouster of Ariad Pharmaceuticals founder and CEO Harvey Berger.
2/20/15 7:09AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
2/13/15 6:00AM
Achillion Pharmaceuticals announced a 10 million-share stock offering Tuesday night.
2/11/15 9:04AM
Whether Regulus can still succeed with a multi-shot regimen or a combination requiring a shot and daily pills will depend on results from studies not yet conducted.
2/9/15 10:05AM
Keryx Biopharmaceuticals gave all 12 of the investment banks with research coverage of the company a slice of its $110 million stock offering.
2/9/15 8:36AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
2/6/15 6:05AM
With shares of Gilead Sciences falling in Wednesday trading after reporting better-than-expected earnings, TheStreet senior columnist Adam Feuerstein breaks down what has investors spooked.
2/4/15 1:38PM
A spokeswoman for the U.S. Army Medical Research Institute says its testing of Alferon and Ampligen drugs for ebola is complete and the relationship has ended.
2/4/15 12:59PM
The debate raging among investors is more about Gilead's future when hepatitis C revenue declines because of few available patients, greater-than-expected discounting and more competition.
2/4/15 7:39AM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,890.53 -245.19 -1.35%
S&P 500 2,076.59 -24.45 -1.16%
NASDAQ 4,937.44 -45.3690 -0.91%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs